Autoimmune Disease Treatment Market Analysis, Overview, Research & Forecast 2027
Autoimmune disease is a medical condition that causes
abnormalities in the immune response and triggers damage to the healthy body
tissues. The increasing prevalence of autoimmune diseases all over the world is
generating high demand for effective treatments in the global market. As per
the report published by Market Research Future (MRFR), the global autoimmune
disease treatment market is anticipated to expand remarkably at a
noteworthy CAGR of 11.2% during the forecast period.
Key Players:
The key players of the global autoimmune disease treatment
market that rea profiled in the report published by MRFR are Abbott
Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec
Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc,
Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR
Biomedical, Johnson & Johnson Inc., Merck & Co. Inc., Siemens, Squibb
Company, Thermo Fisher Scientific, and others.
Market Drivers:
The rise in number of individuals suffering from IBD,
rheumatoid arthritis, psoriasis, sclerosis and other autoimmune diseases is
causing the rise in demand for treatments in the global market, resulting in
the expansion of the global autoimmune disorder treatment market. The
increasing prevalence of common autoimmune disease such as diabetes is one of
the major factors driving the growth of the global autoimmune disease treatment
market.
The pharmaceutical companies are focusing on introducing
highly effective medication and treatments to control and treat the symptoms of
autoimmune diseases by increasing the research and development expenditure,
which in turn is fueling the expansion of the global autoimmune disease
treatment market. The increasing prevalence of other autoimmune diseases such
as Addison’s disease, celiac disease, thyroid disorder and others and the rise
in number of geriatric population affected by autoimmune diseases is causing
the rise in demand for high-quality treatments in the global market, which is
positively impacting the growth of the global autoimmune disease treatment
market.
Market Restraints:
The lack of information regarding the cause of autoimmune
disease, low penetration of advanced treatments in the underdeveloped regions
due to the absence of necessary healthcare infrastructure and lack of awareness
regarding the availability of treatments of autoimmune diseases are likely to
act as a restraint on the expansion of the global autoimmune disease treatment
market during the forecast period.
Market Segmentation:
The global autoimmune disease treatment market has been
segmented on the basis of disease type, diagnosis, therapeutic products and
distribution channel.
Based on disease types, the autoimmune disease treatment
market is segmented into localized and systematic. The localized segment is
sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, autoimmune
hepatitis treatment and others. The systematic disease type segment is
sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.
Based on diagnosis, the autoimmune disease treatment market
is segmented into ELISA, dot blot, line blot, agglutination, double immune
diffusion, western blotting, multiplex immunoassay, and others.
Based on therapeutic products, the autoimmune disease
treatment market is segmented into drugs, and therapeutic and monitoring
equipment. The drugs segment includes biologics, immunosuppressant,
anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory
drugs.
Based on distribution channel, the autoimmune disease
treatment market is segmented into hospitals & clinics, diagnostic centers,
drug stores, pharmacies, and others.
Regional Analysis:
Geographically, the global autoimmune disease treatment
market is segmented into four major regions such as Americas, Europe, Asia
Pacific and the Middle East and Africa. The Americas is projecting dominance on
the global autoimmune disease treatment market owing to the high prevalence of
autoimmune diseases and well-developed healthcare infrastructure in this
region.
The Europe region is projected to account for the second
largest share in the global autoimmune disease treatment market owing to the
increasing investment in the healthcare sector and rise in healthcare
expenditure by the population in this region.
The Asia Pacific region is projecting fastest growth in the
global autoimmune disease treatment market owing to the high population and
increasing pool of individuals suffering from autoimmune diseases in this
region.
The Middle East and Africa region is projecting slow growth
in the global autoimmune disease treatment market owing to the poor healthcare
infrastructure and lack of awareness in the underdeveloped areas of this
region.
Competitive Landscape:
The pharmaceutical companies are focusing on increasing
their research and development expenditure in order to introduce highly
effective and innovative medications in the market which in turn is fueling the
competition in the global autoimmune disease treatment market. The strategic
mergers and acquisitions among the players are aiding the expansion of their
businesses in the global autoimmune disease treatment market.
On 25th July 2018, Corbus Pharmaceuticals, a clinical stage
drug development company, has announced the commencement of the phase 3 study
of Lenabasum for the treatment of dermatomyositis, a rare autoimmune disease.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Comments
Post a Comment